Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI‐Driven Clinical Breakthroughs
Advanced Healthcare Materials · 2026-07 · 15 (28)
DOI: 10.1002/adhm.71370 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, online erschienen am 20.06.2026. Verfasst von Jingru Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Artificial Intelligence, Neutrophils, Nanotechnology, Translational Research, Biomedical. Die Arbeit nennt 216 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Engineered neutrophils, modified via advanced biotechnological tools, are emerging as pivotal agents in translational medicine. By integrating gene editing (e.g., CRISPR‐Cas9), nanotechnology, and artificial intelligence (AI), these cells are redefining precision diagnostics and therapeutics. Gene editing enables precise reprogramming to enhance tumor‐targeting, antimicrobial activity, and immune modulation. Nanotechnology facilitates neutrophil‐bound drug delivery, improving targeting to inflamed or tumor sites while reducing off‐target effects. Simultaneously, AI‐driven platforms analyze multi‐omics data to optimize engineering strategies and personalize treatments. These innovations demonstrate significant promise across clinical domains: in oncology, they deliver cytotoxic payloads and remodel the tumor microenvironment; in infectious diseases, they enhance pathogen clearance; and in autoimmune disorders, they dampen aberrant inflammatory responses. Despite this progress, challenges including off‐target edits, short in vivo persistence, and immune rejection persist. The convergence of microfluidics and high‐throughput screening, coupled with AI‐driven monitoring, is essential to accelerate clinical translation. As interdisciplinary collaboration deepens, engineered neutrophils stand at the forefront of next‐generation medicine, offering versatile, patient‐tailored strategies to bridge the gap between bioengineering breakthroughs and clinical reality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
- School of Ocean and Tropical Medicine, The Second Affiliated Hospital of Guangdong Medical University, Guangdong Medical University, Zhanjiang, China.
- Department of Immunology, School of Medicine, Nantong University, Nantong, China.
ORCID-Profile: Xiao Zhu, Xiaoling Ding
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, J., Xu, J., Aikebaier, S., Liang, Y., Zhou, X., Zhu, X., & Ding, X. (2026). Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI‐Driven Clinical Breakthroughs. Advanced Healthcare Materials, 15(28). https://doi.org/10.1002/adhm.71370
Vancouver
Chen J, Xu J, Aikebaier S, Liang Y, Zhou X, Zhu X, et al. Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI‐Driven Clinical Breakthroughs. Advanced Healthcare Materials. 2026;15(28). doi:10.1002/adhm.71370
BibTeX
@article{Chen2026,
author = {Chen, Jingru and Xu, Jiaqi and Aikebaier, Subinuer and Liang, Youcai and Zhou, Xiaorong and Zhu, Xiao and Ding, Xiaoling},
title = {Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI‐Driven Clinical Breakthroughs},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {28},
doi = {10.1002/adhm.71370}
}
EUVIMED